GO:0031723 CXCR4 chemokine receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031723 (CXCR4 chemokine receptor binding) is a biological_process term describing the binding of a ligand to the C-X-C motif chemokine receptor 4 (CXCR4), a G-protein-coupled receptor.
• CXCR4 binding by its cognate chemokine CXCL12 (SDF-1) controls cell proliferation, migration, homing, and tissue regeneration.
• CXCR4 is a therapeutic target in cancer, inflammation, and viral entry, and its binding can be blocked by small-molecule antagonists such as IT1t and mavorixafor.
• CXCR4 oligomerization and ligand-induced conformational changes are critical for receptor activation and are selectively disrupted by antagonists.
• Dysregulated CXCR4 binding contributes to aldosterone-producing adenomas, Ebola virus entry, and tumor progression.
• CRISPR-based knockout, knock-in, and point-mutation models are essential to dissect CXCR4 ligand-binding specificity and downstream signaling.
Description
GO:0031723, CXCR4 chemokine receptor binding, is a Gene Ontology biological_process term that captures the molecular event of a ligand physically associating with the C-X-C motif chemokine receptor 4 (CXCR4). CXCR4 is a seven-transmembrane G-protein-coupled receptor (GPCR) that binds the chemokine CXCL12 (also known as SDF-1) and mediates diverse cellular responses including chemotaxis, proliferation, and survival. The term is used in annotation to describe any binding event at CXCR4, whether by its natural chemokine ligand or by synthetic antagonists and viral proteins. Researchers study CXCR4 chemokine receptor binding because it is a central node in development, immune surveillance, and tissue regeneration, and because its dysregulation is implicated in cancer metastasis, inflammatory diseases, and viral infections. The binding event is also the target of approved and investigational drugs, such as mavorixafor, which modulates CXCR4 signaling in WHIM syndrome. Understanding the structural and functional consequences of ligand binding at CXCR4 is therefore essential for both basic biology and therapeutic development. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0031723, covering its definition, mechanism, key genes, disease relevance, and experimental models including CRISPR-based approaches.
CXCR4 chemokine receptor binding At A Glance
| GO ID | GO:0031723 |
|---|---|
| GO term | CXCR4 chemokine receptor binding |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Binding of ligands to CXCR4, initiating or blocking downstream signaling |
| Cognate ligand | CXCL12 (SDF-1) |
| Receptor type | G-protein-coupled receptor (GPCR) |
| Therapeutic relevance | Target of small-molecule antagonists (e.g., IT1t, mavorixafor) |
| Disease links | Cancer, WHIM syndrome, Ebola virus entry, aldosterone-producing adenoma |
What Is GO:0031723?
In our own words, GO:0031723 (CXCR4 chemokine receptor binding) is the biological process in which a molecule (such as the chemokine CXCL12, a small-molecule antagonist, or a viral glycoprotein) binds to the CXCR4 receptor. This binding event is the first step in receptor activation or inhibition and is annotated as a process because it initiates downstream signaling or blocks it, depending on the ligand.
Why Is CXCR4 chemokine receptor binding Important in Cell Biology?
CXCR4 chemokine receptor binding is critically important because it governs fundamental processes such as cell migration, proliferation, and tissue regeneration, and its dysregulation drives major human diseases including cancer metastasis, immunodeficiency, and viral pathogenesis. The binding event is also the direct target of clinically approved drugs like mavorixafor, underscoring its translational value.
• Controls chemotaxis and homing of stem cells and immune cells.
• Promotes tumor growth, metastasis, and angiogenesis in multiple cancers.
• Mediates entry of Ebola virus via interaction with viral glycoprotein.
• Involved in aldosterone-producing adenoma, a cause of primary aldosteronism.
• Targeted by small-molecule antagonists for HIV, cancer, and WHIM syndrome.
• Regulates tissue regeneration after injury.
• Oligomerization state affects ligand binding and signaling.
• Structural insights guide rational drug design.
What Happens During CXCR4 chemokine receptor binding?
Ligand recognition and initial binding
In simple terms: The ligand docks onto the receptor like a key in a lock.
CXCR4 binding begins when a ligand, such as the chemokine CXCL12, recognizes the extracellular loops and N-terminus of the receptor. Structural studies have revealed that chemokine receptors engage ligands through a two-step mechanism involving initial recognition and then deeper insertion into the transmembrane binding pocket. This interaction is highly specific and is the first step in receptor activation.
Conformational changes and receptor activation
In simple terms: Binding causes the receptor to change shape and switch on.
Upon ligand binding, CXCR4 undergoes conformational changes that propagate through the transmembrane helices, leading to G-protein coupling and downstream signaling. Antagonist ligands such as IT1t can disrupt this process by selectively interfering with receptor oligomerization, thereby blocking activation.
Oligomerization and modulation of binding
In simple terms: Receptors can pair up, and this pairing affects how they bind ligands.
CXCR4 can form dimers and higher-order oligomers, which influence ligand binding affinity and signaling output. Ward et al. showed that the antagonist IT1t selectively disrupts CXCR4 oligomerization, suggesting that oligomerization is a dynamic regulatory layer in the binding process.
Downstream signaling and cellular responses
In simple terms: Once the receptor is activated, it sends signals inside the cell.
Ligand-bound CXCR4 activates multiple signaling pathways, including G-protein-dependent and beta-arrestin-dependent cascades, which drive cell proliferation, migration, and survival. These responses are context-dependent and are central to tissue regeneration and cancer progression.
Pathological binding events
In simple terms: Sometimes unwanted molecules bind to CXCR4 and cause disease.
Beyond its natural chemokine, CXCR4 can be bound by viral proteins such as Ebola virus glycoprotein, facilitating viral entry. In aldosterone-producing adenomas, CXCR4 overexpression and binding are exploited for molecular imaging. These pathological interactions highlight the need for precise modulation of CXCR4 binding.
Key Genes Involved in GO:0031723 CXCR4 chemokine receptor binding
The following genes and proteins are directly involved in or regulate CXCR4 chemokine receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCR4 | Receptor that binds CXCL12 and other ligands | Primary target for knockout, knock-in, and point-mutation studies |
| CXCL12 | Cognate chemokine ligand for CXCR4 | Used in binding assays and co-culture experiments |
| CXCR7 (ACKR3) | Alternative receptor for CXCL12 | Modulates CXCL12 availability and CXCR4 signaling |
| GNAI1 | G-protein alpha subunit coupled to CXCR4 | Mediates downstream signaling after binding |
| ARRB1 | Beta-arrestin 1 | Regulates receptor desensitization and internalization |
| ARRB2 | Beta-arrestin 2 | Regulates receptor desensitization and internalization |
| GRK2 | G-protein-coupled receptor kinase 2 | Phosphorylates activated CXCR4 |
| GRK5 | G-protein-coupled receptor kinase 5 | Phosphorylates activated CXCR4 |
| IT1t | Small-molecule antagonist | Disrupts CXCR4 oligomerization and binding |
| AMD3100 (Plerixafor) | Small-molecule antagonist | Blocks CXCR4 binding; used clinically |
| Mavorixafor | Small-molecule antagonist | Approved for WHIM syndrome |
| EBOV GP | Ebola virus glycoprotein | Binds CXCR4 to facilitate viral entry |
| CXCR4 (mutants) | Receptor variants with altered binding | Used to map ligand-binding determinants |
| CXCL12 (mutants) | Ligand variants with altered affinity | Used to probe binding specificity |
| CXCR4 oligomers | Higher-order receptor assemblies | Modulate binding and signaling |
| GNAI2 | G-protein alpha subunit | Potential coupling partner |
| GNAI3 | G-protein alpha subunit | Potential coupling partner |
How Is CXCR4 chemokine receptor binding Regulated?
CXCR4 chemokine receptor binding is regulated at multiple levels. Receptor oligomerization can modulate ligand affinity and signaling, and antagonists like IT1t can selectively disrupt oligomerization. Post-translational modifications, including phosphorylation by GRKs and ubiquitination, control receptor desensitization and internalization after ligand binding. Additionally, the availability of the ligand CXCL12 is regulated by scavenger receptors such as CXCR7, which can sequester the chemokine and indirectly affect CXCR4 binding. Transcriptional regulation of CXCR4 expression also influences the overall binding capacity of a cell.
CXCR4 chemokine receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCR4 | Cancer metastasis | Knockout in cancer cell lines; xenograft models |
| CXCR4 | WHIM syndrome | Knock-in of gain-of-function mutations in hematopoietic cells |
| CXCR4 | Ebola virus entry | Overexpression in permissive cells; viral infection assays |
| CXCR4 | Aldosterone-producing adenoma | Knockout in adrenal cell lines; imaging studies |
| CXCL12 | Tissue regeneration | Knockout mice; injury models |
Cancer and metastasis
CXCR4 binding to CXCL12 promotes tumor cell proliferation, migration, and metastasis in multiple cancers. The receptor is overexpressed in many malignancies, and its binding axis is considered a therapeutic target. Antagonists such as AMD3100 have been investigated to block this interaction.
WHIM syndrome
WHIM syndrome is a primary immunodeficiency caused by gain-of-function mutations in CXCR4 that enhance binding and signaling. Mavorixafor, a CXCR4 antagonist, was recently approved for this condition, validating the clinical importance of CXCR4 binding.
Viral infections
Ebola virus glycoprotein can bind CXCR4 to promote viral entry, and this interaction also triggers reticulophagic degradation of the glycoprotein to enhance viral fitness. CXCR4 binding is therefore a determinant of viral pathogenesis.
Endocrine disorders
CXCR4 is overexpressed in aldosterone-producing adenomas, and targeting CXCR4 for molecular imaging has been explored as a diagnostic approach. This highlights the role of CXCR4 binding in endocrine pathology.
From CXCR4 chemokine receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CXCR4 binding drive tumor growth? | CXCR4 knockout cancer cell lines in xenografts |
| How do point mutations affect ligand binding? | CRISPR knock-in of specific CXCR4 mutations |
| Can a tagged CXCR4 be used for imaging? | Knock-in of fluorescent or affinity tags |
| What is the effect of CXCR4 overexpression? | Overexpression in cell lines or transgenic models |
| Which ligands bind CXCR4? | Competition binding assays with mutant receptors |
| How does oligomerization affect binding? | Knock-in of oligomerization-deficient mutants |
How to Study the CXCR4 chemokine receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and receptor density | Characterizing antagonists |
| Surface plasmon resonance | Binding kinetics (kon, koff) | Ligand-receptor interaction studies |
| Calcium flux assay | G-protein activation | Functional screening of ligands |
| Beta-arrestin recruitment | Receptor desensitization | Biased agonism studies |
| Cryo-EM | 3D structure of receptor-ligand complex | Structure-based drug design |
| Flow cytometry | Cell surface CXCR4 levels | Knockout validation |
| Molecular imaging | In vivo CXCR4 expression | Diagnosis of adenomas |
Binding assays
Radioligand binding, surface plasmon resonance (SPR), and isothermal titration calorimetry (ITC) are used to measure affinity and kinetics of ligand binding to CXCR4. These methods are fundamental for characterizing antagonists and mutants.
Structural biology
X-ray crystallography and cryo-electron microscopy have provided high-resolution structures of CXCR4 in complex with ligands, revealing the binding pocket and conformational changes. These structures guide drug design.
Cell-based signaling assays
Calcium flux, cAMP inhibition, and beta-arrestin recruitment assays are used to measure functional consequences of CXCR4 binding. These assays are often combined with CRISPR knockout to validate specificity.
Imaging and flow cytometry
Fluorescently labeled ligands or antibodies can visualize CXCR4 binding and internalization in live cells. Molecular imaging of CXCR4 has been used to detect aldosterone-producing adenomas.
How CRISPR Can Be Used to Study GO:0031723 CXCR4 chemokine receptor binding
Knockout
CRISPR-Cas9 knockout of CXCR4 is used to eliminate receptor expression and study the consequences of loss of binding on cell migration, proliferation, and signaling. Knockout cell lines are essential controls for binding assays.
Point Mutation
Point mutations in CXCR4 can be introduced via CRISPR to mimic disease-associated variants, such as those found in WHIM syndrome, and to map ligand-binding residues. These models help dissect the molecular determinants of binding specificity.
Knock-in
Knock-in of tagged CXCR4 (e.g., fluorescent or epitope tags) allows real-time imaging and biochemical isolation of the receptor without altering its binding properties. Knock-in of mutant CXCR4 can also model gain-of-function diseases.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CXCR4 is used to study the effects of increased receptor density on ligand binding and downstream signaling. Overexpression models are valuable for drug screening.
How EDITGENE Supports CXCR4 chemokine receptor binding Research
Researchers studying CXCR4 chemokine receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for CXCR4 chemokine receptor binding research.
Frequently Asked Questions About CXCR4 chemokine receptor binding
What is CXCR4 chemokine receptor binding?
It is the biological process (GO:0031723) in which a ligand binds to the CXCR4 receptor, initiating or blocking downstream signaling.
What genes are involved in CXCR4 chemokine receptor binding?
Key genes include CXCR4, CXCL12, and signaling partners such as GNAI1, ARRB1, and GRK2.
What diseases are associated with CXCR4 binding?
Cancer metastasis, WHIM syndrome, Ebola virus entry, and aldosterone-producing adenomas.
How is CXCR4 binding studied?
Using binding assays, structural biology, cell-based signaling assays, and imaging.
What are CXCR4 antagonists?
Small molecules like IT1t, AMD3100, and mavorixafor that block ligand binding.
Can CRISPR be used to study CXCR4 binding?
Yes, knockout, knock-in, and point mutations are used to dissect binding mechanisms.
What is the role of CXCL12 in CXCR4 binding?
CXCL12 is the primary chemokine ligand that binds CXCR4 to activate signaling.
How does CXCR4 oligomerization affect binding?
Oligomerization can modulate ligand affinity and is disrupted by antagonists like IT1t.
Is CXCR4 a therapeutic target?
Yes, it is targeted in cancer, WHIM syndrome, and HIV.
What model systems are used for CXCR4 binding research?
Cell lines with CRISPR modifications, xenografts, and imaging models.
Conclusion
GO:0031723 (CXCR4 chemokine receptor binding) is a fundamental biological process that controls cell migration, proliferation, and survival, with broad implications for cancer, immunodeficiency, and viral infection. The binding event is a validated therapeutic target, and its structural and functional dissection continues to yield insights into GPCR biology. CRISPR-based models are indispensable for studying CXCR4 binding, and EDITGENE offers a full range of services to accelerate this research. By combining precise gene editing with functional assays, researchers can uncover new mechanisms and therapeutic opportunities.
References
- 1. Heinze B et al.. 2018. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.. Hypertension 71(2):317-325 PMID: 29279316
- 2. Bianchi ME et al.. 2020. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration.. Front Immunol 11:2109 PMID: 32983169
- 3. Ward RJ et al.. 2021. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.. J Biol Chem 296:100139 PMID: 33268380
- 4. Huang H et al.. 2025. Dual roles of CXCR4 (C-X-C motif chemokine receptor 4) in promoting entry of ebolavirus and targeting excessive glycoprotein for reticulophagic degradation to facilitate viral fitness.. Autophagy 21(10):2148-2167 PMID: 40223186
- 5. Hoy SM. 2024. Mavorixafor: First Approval.. Drugs 84(8):969-975 PMID: 39004659
- 6. Khan A et al.. 2007. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.. Curr Med Chem 14(21):2257-77 PMID: 17896975
- 7. Arimont M et al.. 2017. Structural Analysis of Chemokine Receptor-Ligand Interactions.. J Med Chem 60(12):4735-4779 PMID: 28165741
- 8. Teixidó J et al.. 2018. The good and bad faces of the CXCR4 chemokine receptor.. Int J Biochem Cell Biol 95:121-131 PMID: 29288743
